Molecular targeted therapies for pediatric atypical teratoid/rhabdoid tumors

Pediatr Investig. 2022 May 23;6(2):111-122. doi: 10.1002/ped4.12325. eCollection 2022 Jun.

Abstract

Atypical teratoid/rhabdoid tumors (AT/RTs) are lethal central nervous system tumors, which are primarily diagnosed in infants. Current treatments for AT/RTs include surgery, radiotherapy, and chemotherapy; these treatments have poor prognoses and challenging side effects. The pivotal genetic event in AT/RT pathogenesis comprises the inactivation of SMARCB1 or SMARCA4. Recent epigenetic studies have demonstrated mutual and subtype-specific epigenetic derangements that drive tumorigenesis; the exploitation of these potential targets might improve the dismal treatment outcomes of AT/RTs. This review aims to summarize the literature concerning targeted molecular therapies for pediatric AT/RTs.

Keywords: Atypical teratoid/rhabdoid tumors; SMARCA4; SMARCB1; SWI/SNF complex; Targeted molecular therapy.

Publication types

  • Review